Kevin R. Sayer Insider Information

Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.

Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.

He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.

Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic.

Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.

He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.

Within the last three months, Kevin R.. Sayer has sold $2,281,054.00 in shares of DexCom stock. Most recently, Kevin R. Sayer sold 6,221 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $366.67, for a transaction totalling $2,281,054.07.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/5/2021	Sell	6,221	$366.67	$2,281,054.07
3/9/2021	Sell	3,857	$361.11	$1,392,801.27
2/1/2021	Sell	12,468	$378.17	$4,715,023.56
1/12/2021	Sell	39,949	$362.09	$14,465,133.41
12/1/2020	Sell	13,233	$322.18	$4,263,407.94
10/29/2020	Sell	13,830	$340.14	$4,704,136.20
9/9/2020	Sell	9,965	$398.30	$3,969,059.50
7/6/2020	Sell	6,000	$420.94	$2,525,640.00
6/1/2020	Sell	6,000	$376.57	$2,259,420.00
5/4/2020	Sell	6,000	$344.63	$2,067,780.00
4/7/2020	Sell	6,000	$262.81	$1,576,860.00
3/11/2020	Sell	20,374	$264.82	$5,395,442.68
3/9/2020	Sell	6,000	$269.02	$1,614,120.00
2/10/2020	Sell	6,000	$242.39	$1,454,340.00
1/13/2020	Sell	6,000	$230.62	$1,383,720.00
12/2/2019	Sell	10,000	$221.37	$2,213,700.00
11/4/2019	Sell	10,000	$157.50	$1,575,000.00
10/1/2019	Sell	10,000	$149.60	$1,496,000.00
9/9/2019	Sell	14,322	$149.86	$2,146,294.92
9/3/2019	Sell	10,000	$170.13	$1,701,300.00
8/15/2019	Sell	10,000	$156.12	$1,561,200.00
7/8/2019	Sell	6,000	$146.25	$877,500.00
6/10/2019	Sell	6,000	$132.74	$796,440.00
5/13/2019	Sell	6,000	$115.73	$694,380.00
4/15/2019	Sell	6,000	$118.91	$713,460.00
3/12/2019	Sell	32,566	$142.83	$4,651,401.78
2/11/2019	Sell	6,000	$148.90	$893,400.00
1/14/2019	Sell	6,000	$140.99	$845,940.00
12/10/2018	Sell	11,162	$121.67	$1,358,080.54
11/12/2018	Sell	11,161	$146.43	$1,634,305.23
10/8/2018	Sell	11,161	$124.76	$1,392,446.36
9/10/2018	Sell	25,495	$143.62	$3,661,591.90
8/13/2018	Sell	11,161	$123.22	$1,375,258.42
7/9/2018	Sell	14,219	$99.79	$1,418,914.01
12/12/2017	Sell	6,000	$58.85	$353,100.00
11/20/2017	Sell	12,000	$55.00	$660,000.00
9/20/2017	Sell	6,000	$69.34	$416,040.00
8/11/2017	Sell	6,000	$69.77	$418,620.00
7/12/2017	Sell	6,000	$71.86	$431,160.00
6/12/2017	Sell	6,000	$69.07	$414,420.00
10/14/2016	Sell	7,000	$81.87	$573,090.00
9/14/2016	Sell	7,000	$91.79	$642,530.00
8/15/2016	Sell	7,000	$90.78	$635,460.00
7/13/2016	Sell	7,000	$79.92	$559,440.00
6/20/2016	Sell	35,000	$75.00	$2,625,000.00

Kevin R. Sayer Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $382.89

$373.10

$383.17

50 Day Range

MA: $370.65

$339.15

$418.94

52 Week Range

Now: $382.89

$270.11

$456.23

Volume

431,350 shs

Average Volume

853,048 shs

Market Capitalization

$36.83 billion

P/E Ratio

158.22

Dividend Yield

N/A

Beta

0.86